KRAS and lung adenocarcinoma: The therapeutic efficacy of CDK4 kinase inhibition is restricted in the treatment of KRAS-driven lung adenocarcinomas; however, an intriguing approach involving the combination of CDK4 kinase inhibition and elimination of CRAF expression has demonstrated acceptable toxicities in preclinical in vivo studies [81].